Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Industry Valuation for the Bioengineered Protein Drugs Sector?
In recent times, there has seen a notable surge in the market size of bioengineered protein drugs. It is set to increase from $406.39 billion in 2024 to $435.17 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.1%. The surge in the previous period has stemmed from enhanced disease comprehension, regulatory consents, the escalating occurrence of persistent ailments, partnerships and associations, along with market proliferation.
In the forthcoming years, the market for bioengineered protein drugs is projected to experience robust growth. The market size is expected to reach $593.3 billion in 2029, growing at a compound annual growth rate (CAGR) of 8.1%. Personalized medicine trends, emerging markets, expanding curative applications, an emphasis on rare diseases, and enhancements in healthcare infrastructure can be attributed to the market growth forecasted for this period. The major trends during the predicted period encompass advances in protein engineering, augmented attention on monoclonal antibodies, personalized medicine and targeted therapies, the emergence of next-generation biologics, and optimization of the manufacturing process.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10180&type=smp
What Forces Are Driving The Growth Of The Bioengineered Protein Drugs Market?
The escalating incidence of chronic illnesses is anticipated to fuel the expansion of the bioengineered protein drug market. Chronic illnesses are those that people endure for a year or more, necessitate ongoing medical care, and inhibit daily physical activities. Bioengineered protein drugs, with custom-made protein therapies, are employed for treating chronic illnesses, especially in areas like oncology and regenerative medicine, using a combination of techniques and logical methodologies. For example, the World Health Organization (WHO) reported in its 2022 Highlights that in September 2022, there were 41 million fatalities, 74% of which were due to noncommunicable diseases (NCDs) or chronic diseases. Out of these, 17.9 million deaths were due to cardiovascular diseases, 9.3 million were due to cancer, 4.1 million due to chronic respiratory diseases, and 2.0 million due to diabetes. Consequently, the rising occurrence of chronic disease is a key factor propelling the growth of the bioengineered protein drugs market.
How Is The Bioengineered Protein Drugs Industry Segmented Across Key Parameters?
The bioengineered protein drugs market covered in this report is segmented –
1) By Drug Type: Recombinant Protein, Vaccine, Peptide Antibiotics, Therapeutic Enzymes, Other Drug Type
2) By Technology: Bioreactors, Fractionation, Genetically Modified Organisms, Genetic Engineering, Pharming, Cell Culture, Microbial Cell Fermentation, Other Technology
3) By Application: Autoimmune, Heart, Congenital, Infectious Diseases, Cancer, Diabetes, Arthritis, Other Application
4) By End User: Pharmaceutical, Contract Research Organizations, Research Institutes, Biotechnology Companies
Subsegments:
1) By Recombinant Protein: Monoclonal Antibodies, Hormones, Cytokines
2) By Vaccine: Recombinant Vaccines, DNA Vaccines
3) By Peptide Antibiotics: Lipopeptide Antibiotics, Glycopeptide Antibiotics
4) By Therapeutic Enzymes: Enzyme Replacement Therapies, Biosimilar Enzymes
5) By Other Drug Type: Fusion Proteins, Antibody-Drug Conjugates (ADCs)
What Notable Trends Are Shaping The Direction Of The Bioengineered Protein Drugs Market?
Key players in the bioengineered protein drug market are implementing the strategy of forming strategic alliances with businesses and governments in order to deliver crucial bioengineered protein drugs. Strategic alliances entail corporations pooling their strengths and resources for mutual advantages and accomplishments. For example, in June 2023, Future Fields, a biotech firm based in Canada, formed a collaboration with Jenthera Therapeutics, another Canadian biotech company specializing in the creation of unique methods for rare and intricate health disorders. The goal of this collaboration is to create an innovative protein for cancer treatment using Future Fields’ EntoEngine platform for cost-efficient and sustainable large-scale production.
Which Companies Currently Dominate The Competitive Landscape In The Bioengineered Protein Drugs Industry?
Major companies operating in the bioengineered protein drugs market include Abbvie Inc., Amgen Inc., Astrazeneca PLC, Bayer HealthCare Pharmaceuticals LLC, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Novo Nordisk A/S, Sanofi S.A., Grifols S.A., Adma Biologics Inc., CSL Limited, Abbott Laboratories, Baxter International Inc., Fresenius Kabi AG, Merck & Co. Inc., Pfizer Inc., Biogen Inc., Bristol-Myers Squibb Company, Genentech Inc., Lonza Group AG, MedImmune LLC, Regeneron Pharmaceuticals Inc., Shire plc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Shanghai United Cell Biotechnology Co. Ltd., Panacea Biotec Ltd.
Get The Full Report Here:
https://www.thebusinessresearchcompany.com/report/bioengineered-protein-drugs-global-market-report
Which Geographic Regions Are Driving Demand In The Bioengineered Protein Drugs Market?
North America was the largest region in the bioengineered protein drugs market in 2024. The regions covered in the bioengineered protein drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10180&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
